sibutramine formerly sold brand name meridia among others appetite suppressant discontinued many countries works reuptake inhibitor similar tricyclic antidepressant widely marketed prescribed adjunct treatment obesity along diet exercise associated increased cardiovascular diseases strokes withdrawn market several countries regions including european hong mexico new united united however drug remains available sibutramine originally developed boots nottingham manufactured marketed abbott laboratories sold variety brand names including reductil meridia siredia sibutrex withdrawal markets classified schedule iv controlled substance united states fda still found sibutramine diet supplements marketed natural traditional herbal remedies sibutramine used produce appetite suppression purpose attaining weight loss treatment patients obesity sibutramine contraindicated patients higher number cardiovascular events observed people taking sibutramine versus control vs fda noted concerns sibutramine increases risk heart attacks strokes patients history cardiovascular frequently encountered side effects dry mouth paradoxically increased appetite nausea strange taste mouth upset stomach constipation trouble sleeping dizziness drowsiness menstrual crampspain headache flushing jointmuscle pain cochrane review sibutramine found substantially increase blood pressure heart rate patients updated review sibutramine included since drug withdrawn used regular blood pressure monitoring needed performed following side effects infrequent serious require immediate medical attention cardiac arrhythmias paresthesia mentalmood changes eg excitement restlessness confusion depression rare thoughts suicide symptoms require urgent medical attention seizures problems urinating abnormal bruising bleeding melena hematemesis jaundice fever rigors chest pain hemiplegia abnormal vision dyspnea edema currently case pulmonary hypertension noted fenfluramine fenphen combo forced excess release different action phentermine uninvolved clinically issues fenfluramine sibutramine number clinically significant interactions concomitant use sibutramine monoamine oxidase inhibitors maois selegiline indicated may increase risk serotonin syndrome somewhat rare serious adverse drug sibutramine taken within two weeks stopping starting maoi taking sibutramine certain medications used treatment ergolines well opioids may also increase risk serotonin syndrome may use one serotonin reuptake inhibitor concomitant use sibutramine drugs inhibit ketoconazole erythromycin may increase plasma levels sibutramine affect efficacy hormonal sibutramine reuptake inhibitor snri humans reduces reuptake norepinephrine serotonin dopamine thereby increasing levels substances synaptic clefts helping enhance satiety serotonergic action particular thought influence appetite older anorectic agents amphetamine fenfluramine force release neurotransmitters rather affecting sibutramines mechanism action similar tricyclic antidepressants demonstrated antidepressant effects animal models approved us food drug administration fda november treatment obesity sibutramine reported prodrug two active metabolites desmethylsibutramine didesmethylsibutramine much greater potency monoamine reuptake studies indicated renantiomers metabolite exert significantly stronger anorectic effects unlike serotonergic appetite suppressants like fenfluramine sibutramine metabolites low likely inconsequential affinity sibutramine well absorbed gastrointestinal tract undergoes considerable firstpass metabolism reducing bioavailability drug reaches peak plasma level hour also halflife hour sibutramine metabolized cytochrome isozyme two pharmacologically active primary secondary amines called active metabolites halflives hours respectively peak plasma concentrations active metabolites reached three four hours following metabolic pathway mainly results two inactive conjugated hydroxylated metabolites called metabolites metabolites mainly excreted urine sibutramine usually used form hydrochloride monohydrate salt sibutramine two active ndemethylated metabolites may measured biofluids liquid chromatographymass spectrometry plasma levels three species usually μgl range persons undergoing therapy drug parent compound norsibutramine often detectable urine dinorsibutramine generally present concentrations sibutramine originally developed boots nottingham marketed knoll pharmaceuticals basfknoll ag purchased boots research division classified schedule iv controlled substance united states us fda approved weight loss maintenance weight loss people bmi greater equal people bmi cardiovascular risk factors manufactured marketed abbott sold variety brand names including reductil meridia siredia sibutrex studies looked reports sudden death heart failure renal failure gastrointestinal problems despite petition ralph naderfounded ngo public fda made attempts withdraw drug part senate hearing similarly david graham fda whistleblower testified senate finance committee hearing sibutramine may dangerous conditions used january november large randomizedcontrolled sibutramine cardiovascular outcomes scout study patients examined whether sibutramine administered within weight management program reduces risk cardiovascular complications people high risk heart disease concluded use silbutramine rr primary outcome composit nonfatal mi nonfatal cva cardiac arrest cv april david haslam chairman national obesity forum said dissenting article sibutramine gone forgotten scout study flawed covered highrisk patients consider obese patients cardiovascular complications similar january european medicines agency recommended suspension marketing authorizations sibutramine based scout study august fda added new contraindication patients years age clinical studies sibutramine include sufficient numbers october fda recommended continued prescribing unnecessary cardiovascular risks patients asking abbott laboratories voluntarily abbott announced day withdrawing sibutramine us market citing concerns minimal efficacy coupled increased risk adverse cardiovascular december united states food drug administration issued alert consumers naming different products marketed dietary supplements weight loss illegally contain undisclosed amounts march dieter müller et al published study sibutramine poisoning cases similar chinese herbal supplements sold europe containing much twice dosage legally licensed additional products recalled fda april underscoring risks associated unregulated herbal supplements unsuspecting persons concern especially relevant underlying medical conditions incompatible undeclared pharmaceutical january similar alert issued counterfeit versions overthecounter weight loss drug alli sold internet instead active ingredient orlistat counterfeit drugs contain sibutramine concentrations least twice amount recommended weight march health canada advised public illegal herbal diet natural found market containing sibutramine prescription drug canada without listing sibutramine october fda notified consumers slimming beauty bitter orange slimming capsules contain active pharmaceutical ingredient sibutramine prescriptiononly drug stimulant sibutramine listed product october mhra uk issued warning regarding payouji tea pai guo slim capsules found contain undeclared quantities december fda released warning regarding fruta planta dietary products found contain undeclared amounts sibutramine recall stated safe formula us market versions fruta planta contain sibutramine versions formula unsafe purchased illegal weight loss products imported ireland found contain similar concerns raised australia illegal imported supplements found contain sibutramine resulting public alerts australias therapeutic goods october fda warned brands dietary supplements tainted study fda found synthetic additives including sibutramine diet supplements marketed natural traditional herbal stimulants phenylethanolamine httpsenwikipediaorgwikisibutramine